Fujita Health University concluded a clinical study of the antiviral drug Avigan and report it has failed to demonstrate a clear efficacy in treating SARS-CoV-2 patients in the early stage of the infection. The Japanese university reports that the delta between those patients who were given Avigan (Favipiravir) and those who took it later was not statistically relevant for purposes of statistically evaluating the effectiveness of the drug. Developed by a subsidiary of Fujifilm Holdings Corp (Toyama Chemical), principal investigator Yohei Doi acknowledged that the drug has exhibited impact in addressing COVID-19 and that the study size of 89 patients make it too small to yield a statistically meaningful difference.
Favipiravir (Avigan): Is it a Treatment or Not?
This depends on what part of the world one is in; who one speaks with and probably a number of other factors. Now a generic drug, it has been approved in China, India and Russia as an effective treatment for COVID-19. As TrialSite News reported recently, the “Dhaka Trial” showed “clear cut evidence” an effective outcome. Moreover, the drug’s developer, Fujifilm Toyama Chemical Co. is sponsoring clinical trials in key...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).